Commercial/Healthcare Exchange PA Criteria
Effective: November 13, 2019

Prior Authorization: Duaklir Pressair

Products Affected: Duaklir Pressair (aclidinium and formoterol) powder for inhalation 400 mcg/12 mcg

Medication Description: Duaklir Pressair is a breath-actuated multi-dose dry powder inhaler for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Duaklir Pressair is a combination of two bronchodilators, aclidinium and formoterol. Aclidinium is a long-acting antimuscarinic antagonist. It competitively and reversibly inhibits the action of acetylcholine at type 3 muscarinic (M3) receptors in bronchial smooth muscle causing bronchodilation. Formoterol is a long-acting selective beta2-adrenergic receptor agonist. It relaxes bronchial smooth muscle by selective action on beta2 receptors with little effect on heart rate.

Covered Uses: Maintenance treatment of patients with chronic obstructive pulmonary disease (COPD)

Exclusion Criteria:
1. Severe hypersensitivity to milk proteins
2. Relief of acute bronchospasm
3. Treatment of asthma

Required Medical Information:
1. Diagnosis
2. Previous therapies tried/failed

Age Restrictions: 18 years of age and older

Prescriber Restrictions: N/A

Coverage Duration: 12 months

Other Criteria:
A. Patient has a diagnosis of Chronic Obstructive Pulmonary Disease (COPD): **AND**
B. Patient has a documented intolerance to, or treatment failure, of an adequate trial of Anoro Ellipta **AND** Stiolto Respimat.

References:
1. Duaklir Pressair [package insert]. Morrisville, NC; Circassia Pharmaceuticals Inc.; March 2019.
2. Aclidinium and Formoterol. Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL.
3. "Chronic Obstructive Pulmonary Disease (COPD)." World Health Organization, World Health Organization, 21 Sept. 2017, www.who.int/respiratory/copd/en/.
4. COPD: Stages, Causes, Treatment, and More." Healthline, Healthline Media, 29 Mar. 2019, www.healthline.com/health/copd.

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	11/13/19